ArticlePulmonary therapy2026
Potential Public Health Impact of Updated COVID-19 Vaccination Strategies in Malaysia: Epidemiological Data Update.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study estimated the potential public health and economic impacts of different COVID-19 vaccination strategies in Malaysia using an updated COVID-19 vaccine.
methodsA previously published Markov decision-tree model (2021-2022) was updated with the latest epidemiology data from Malaysia (October 2022-September 2023). This updated model was used to assess the outcomes of alternative vaccination strategies using the updated COVID-19 vaccine. Age-specific inputs were derived from Malaysian epidemiological data and published sources. The model projected health outcomes (cases, hospitalizations, and deaths) and economic outcomes (direct medical costs and productivity losses) across various age and risk categories.
resultsVaccinating individuals aged 60 and above, as well as high-risk individuals aged 6 months to 59 years with vaccine coverage of 20%, was projected to prevent 91,824 infections, 1477 hospitalizations, and 53 deaths. The model estimated total savings of MYR 90.9 million in direct medical costs attributed to COVID-19 treatment and MYR 110.4 million in indirect costs attributed to COVID-19 illness. Expanding coverage among individuals aged 60 and above, as well as high-risk individuals of any age, to 50% could further increase the reduction in deaths, hospitalizations, infections, and costs by up to 150%.
conclusionsWhen considering recent updated epidemiology data and expected vaccination coverage, vaccination strategies appear to have a smaller impact, largely caused by the reduction in vaccine coverage. However, despite this, using an updated COVID-19 vaccine could still reduce the health and economic burden of COVID-19 in terms of cases, hospitalizations, deaths, direct medical costs, and indirect productivity losses in Malaysia, especially among high-risk populations and older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.